BTAI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
182.0K
-11.7%
206.0K
-19.5%
256.0K
+161.2%
98.0K
-18.3%
120.0K
Cost of Revenue
22.0K
-92.2%
283.0K
+784.4%
32.0K
+190.9%
11.0K
-89.7%
107.0K
Gross Profit
160.0K
+307.8%
-77000
-134.4%
224.0K
+157.5%
87.0K
+569.2%
13.0K
Operating Expenses
10.4M
+2.0%
10.1M
-3.4%
10.5M
-26.6%
14.3M
-9.8%
15.9M
R&D
3.2M
+7.1%
3.0M
-55.9%
6.7M
-23.3%
8.7M
-14.8%
10.3M
SG&A
7.2M
-0.0%
7.2M
+89.0%
3.8M
-29.3%
5.4M
-4.1%
5.6M
Operating Income
-10193000
+0.3%
-10223000
+0.6%
-10282000
+27.7%
-14228000
+10.2%
-15852000
EBITDA
-10175000
-0.1%
-10165000
+0.4%
-10208000
+26.9%
-13959000
+11.5%
-15777000
Net Income
-14713000
-15.9%
-12691000
-1.2%
-12545000
+59.4%
-30911000
-61.1%
-19187000
EPS (Basic)
$-0.49
+9.3%
$-0.54
+5.3%
$-0.57
+73.9%
$-2.18
+11.0%
$-2.45
EPS (Diluted)
$-0.49
+9.3%
$-0.54
+5.3%
$-0.57
+73.9%
$-2.18
+11.0%
$-2.45
Shares (Diluted)
30.3M
+28.5%
23.6M
+7.3%
22.0M
+54.7%
14.2M
+81.0%
7.8M
BioXcel Therapeutics (BTAI) โ€” Financials